The Quantellect read.As of Nov 19, 2026, 13 active firms cover Nektar Therapeutics: 9 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $50.00 to $192.00 (about 3.8x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $129.82 sits 277% above the current $34.45. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 8 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.51 next quarter toward $-9.80 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Buy
Strong Buy00%
Buy969%
Neutral431%
Sell00%
Strong Sell00%
Based on 13 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$129.82
+276.8% upside
Average target across 11 active firms as of Nov 19, 2026 vs $34.45 current
Highest Target$192.00
Average Target$129.82
Lowest Target$50.00
Detailed analyst forecasts for NKTR
Showing 1–13 of 13 named analysts shown · 13 active firms in the rating projection
As of Nov 19, 2026, 9 of 13 active firms rate NKTR a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NKTR EPS & revenue forecast
EPS · NEXT QUARTER
$-2.51
Range $-3.50 – $-1.73 · 11 analysts · +38% YoY
Next period, 11 analysts expect Nektar Therapeutics to earn $-2.51 a share (range $-3.50 – $-1.73), versus $-1.82 a year earlier. Full-year consensus is $-7.21, growing to $-9.80 the year after.
REVENUE · NEXT QUARTER
$8.8M
Range $2.0M – $11.1M · 11 analysts · -19% YoY
Revenue is expected to reach $8.8M (range $2.0M – $11.1M), -19.0% year-over-year. Full-year consensus is $40.7M, rising to $51.4M next year.
Top analysts covering Nektar Therapeutics
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NKTR.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$150.00+335.4% to target
Overall win rate
49%
+ Follow
#2
Jessica Fye
JP Morgan · Rank #100
Neutral
$65.00+88.7% to target
Overall win rate
54%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$150.00+335.4% to target
Overall win rate
43%
+ Follow
#4
Julian Harrison
BTIG · Rank #183
Buy
$178.00+416.7% to target
Overall win rate
41%
+ Follow
#5
Arthur He
HC Wainwright & Co. · Rank #198
Buy
$185.00+437.0% to target
Overall win rate
50%
+ Follow
NKTR stock forecast FAQ
What is NKTR's average 12-month price target?+
The 11 active firms with a live target average $129.82 for Nektar Therapeutics over the next 12 months, ranging from a $192.00 high to a $50.00 low, as of Nov 19, 2026.
Is NKTR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 13 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NKTR?+
The Street-high target is $192.00 (Piper Sandler), and the Street-low is $50.00 (Wedbush). The average of all 11 active-firm targets is $129.82.
How many active Wall Street firms cover NKTR?+
13 active firms have a recognized rating on Nektar Therapeutics as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NKTR?+
Among analysts who currently cover NKTR, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $150.00 target.
What is Nektar Therapeutics's projected EPS for next quarter?+
The consensus estimate is $-2.51 per share (range $-3.50 – $-1.73) across 11 analysts. Full-year EPS is projected at $-7.21, rising to $-9.80 the following year.
How much revenue is Nektar Therapeutics expected to report next quarter?+
Consensus revenue is $8.8M (range $2.0M – $11.1M). Full-year revenue is projected at $40.7M, growing to $51.4M next year.
Have analysts been upgrading or downgrading NKTR lately?+
As of Nov 19, 2026, 9 of 13 active firms rate NKTR a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NKTR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.